Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2009 |
| gptkbp:ATCCode |
L04AC07
|
| gptkbp:brand |
gptkb:tocilizumab
|
| gptkbp:CASNumber |
375823-41-9
|
| gptkbp:contraindication |
active infections
|
| gptkbp:developedBy |
gptkb:Roche
|
| gptkbp:form |
solution for injection
solution for infusion |
| https://www.w3.org/2000/01/rdf-schema#label |
RoActemra
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:interleukin-6_receptor
|
| gptkbp:mechanismOfAction |
IL-6 receptor antagonist
|
| gptkbp:monoclonalAntibodyType |
humanized
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
headache
hypertension infections elevated liver enzymes |
| gptkbp:usedFor |
gptkb:juvenile_idiopathic_arthritis
gptkb:giant_cell_arteritis rheumatoid arthritis cytokine release syndrome COVID-19 (in some cases) |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:tocilizumab
gptkb:Roche_Holding gptkb:F._Hoffmann-La_Roche_AG |
| gptkbp:bfsLayer |
7
|